Dr. Mark Hyman on Function Health & GLP-1 microdosing | E2334

Dr. Mark Hyman critiques the American healthcare system, highlighting its inefficiencies, particularly in technology use for decision-making. He reveals that one in three Americans avoid doctor visits due to costs, while a staggering 93% of those with metabolic dysfunction are not receiving proper care. Hyman advocates for functional health, which focuses on empowering individuals with their health data and addressing root causes rather than merely treating symptoms.

He points out alarming statistics, such as 75% of Americans being overweight or obese and 65% having unchecked high insulin levels. The functional health model has conducted over 100 million biomarker tests, indicating a significant gap in preventive care. Hyman emphasizes the importance of early detection in cancer, referencing the Gallerate test, which boasts a 75% effectiveness rate.

The discussion also covers the potential of AI in healthcare, with large language models demonstrating accuracy comparable to doctors. Hyman envisions a future in P4 Medicine—preventive, predictive, personalized, and participatory—while acknowledging the challenges of sharing medical records due to HIPAA compliance. He stresses the need for more information to be available to doctors to improve patient care.

Hyman highlights the underestimated negative impacts of alcohol and sugar on health, linking them to the poor metabolic health of 93% of Americans. He estimates that between one in two to three in four Americans may have pre-diabetes, underscoring the importance of insulin as a health biomarker, which is often overlooked by doctors despite its low testing cost. He argues that insulin levels are more critical than blood sugar levels for assessing health and emphasizes the importance of balancing blood sugar for healthy aging.

The conversation shifts to GLP-1 medications, which Hyman notes can aid in weight loss and metabolic health. He acknowledges a growing interest in these medications, although some doctors are hesitant to prescribe them to non-diabetic patients. Hyman predicts increased acceptance of GLP-1s for weight management but warns that they are not a panacea and come with potential side effects, including a 4% serious adverse effect rate and digestive issues for 75% of users. He raises concerns about muscle loss associated with GLP-1 use and stresses the importance of strength training for maintaining muscle and metabolic health.

Hyman also addresses the overdiagnosis of mental illness and the overprescription of SSRIs, noting that many individuals on these medications feel they have lost significant time in their lives. He attributes the mental health crisis to factors like low levels of essential nutrients, including omega-3s and vitamin D. He advocates for nutritional and metabolic psychiatry, supported by research from institutions like Harvard and Stanford, and identifies the ultra-processed diet as a major contributor to mental health issues.

He emphasizes the need to treat underlying causes in psychiatric practices, citing a study showing that providing whole real food in detention centers significantly reduced violent crime and suicide rates among teenage boys. Hyman outlines five foundational elements for mental health: diet, exercise, sleep, meditation, and socialization. He notes a revolution in psychiatry that includes both nutritional metabolic psychiatry and psychedelic psychiatry, although he cautions that psychedelic treatments require careful scientific investigation before widespread use.

Early data on psychedelics shows promise for conditions like PTSD and depression, suggesting they may promote brain repair and neuroplasticity. Hyman concludes that the field of medicine, particularly psychiatry, is undergoing significant changes, with functional health leading the way.